Anthony Martinez
Family · Las Vegas, NVNPI 1770262594
Payments from drug & device makers
Across 89 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$397
- Pfizer$268
- Novo Nordisk$254
- Amgen$173
- AbbVie$172
- Dexcom, Inc.$167
- plus $642 from 15 others
What the payments were for
- Food & beverage$2,02998%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $397 |
| Pfizer | 12 | $268 |
| Novo Nordisk | 14 | $254 |
| Amgen | 7 | $173 |
| AbbVie | 9 | $172 |
| Dexcom, Inc. | 3 | $167 |
| Lilly USA, LLC | 5 | $122 |
| Daiichi Sankyo Inc. | 5 | $96 |
| Otsuka America Pharmaceutical, Inc. | 4 | $91 |
| Antares Pharma, Inc. | 2 | $76 |
| GSK | 2 | $50 |
| Chiesi USA, Inc. | 1 | $27 |
| Corcept Therapeutics | 1 | $26 |
| Nalu Medical, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Edwards Lifesciences | 1 | $22 |
| Viatris Specialty LLC | 1 | $20 |
| Bayer | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Halozyme Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,074 in reported general payments places this provider in the 80th percentile of 1,501 family providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $45,482 |
| MounjaroTirzepatide | 27 | $43,830 |
| EliquisApixaban | 26 | $30,539 |
| FarxigaDapagliflozin Propanediol | 15 | $25,981 |
| JardianceEmpagliflozin | 18 | $21,091 |
| XareltoRivaroxaban | 14 | $8,590 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $3,096 |
| Fenofibrate | 15 | $2,848 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,511 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,211 |
| Testosterone Cypionate | 37 | $1,167 |
| Atorvastatin Calcium | 121 | $937 |
| Levothyroxine Sodium | 76 | $728 |
| Gabapentin | 43 | $716 |
| Amlodipine Besylate | 91 | $698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $254 | $45,48235 claims |
| Lilly USA, LLCMounjaro | $122 | $43,83027 claims |
| PfizerEliquis | $268 | $30,53926 claims |
| AstraZenecaFarxiga | $397 | $25,98115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,501 family providers in Nevada.
Other family in Las Vegas
- John PhoenixLas Vegas$281K
- Hollie TylerLas Vegas$118K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
- Kelly PapeshLas Vegas$44K
- Erin WilkinsonLas Vegas$43K
- Anna Melisa Lopez-SanglayLas Vegas$42K
- Bernard BlanksLas Vegas$26K
- Hillary DursteinLas Vegas$21K
- Victoria HughesLas Vegas$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.